Depressive Disorder News and Research

RSS

FDA approves PRISTIQ for the treatment of adult patients with major depressive disorder

Wyeth Pharmaceuticals, a division of Wyeth, has announced that the U.S. Food and Drug Administration (FDA) has approved PRISTIQ (desvenlafaxine), a structurally novel, once-daily serotonin-norepinephrine reuptake inhibitor (SNRI), to treat adult patients with major depressive disorder (MDD).

3 Mar 2008

AstraZeneca submits sNDA for SEROQUEL XR for treatment of major depressive disorder

AstraZeneca has announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for once- daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of major depressive disorder (MDD) as monotherapy, adjunct therapy, and maintenance therapy in adult patients.

1 Mar 2008

Depressed teens respond well to combination therapy

More than half of teenagers with the most debilitating forms of depression that do not respond to treatment with selective serotonin reuptake inhibitors (SSRIs) show improvement after switching to a different medication combined with cognitive behavioral therapy, researchers at UT Southwestern Medical Center and their colleagues in a multicenter study have found

27 Feb 2008

Adding therapy helps adolescents with depression not responding to SSRIs

For adolescents with depression not responding to an initial treatment with a selective serotonin reuptake inhibitor (SSRI; a class of antidepressant drugs), switching medications and adding cognitive behavioral therapy resulted in an improvement in symptoms, compared to just changing medications, according to a study in the February 27 issue of JAMA: The Journal of the American Medical Association.

27 Feb 2008

Study suggests Risperidone long-acting injection combined with standard treatment helped delay time to relapse in patients with bipolar disorder

Patients with frequently relapsing bipolar disorder had a significant delay in the time to an initial relapse when risperidone long-acting injection (RLAI) was combined with standard treatment, according to a new study. The study compared patients who received RLAI and standard treatment to those who received standard treatment combined with placebo.

4 Feb 2008

Matters of the mind can affect matters of the heart

A new study by McGill University and Université de Montréal researchers has found that major anxiety and/or depression, can double a coronary artery disease patient's chances of repeated heart ailments.

21 Jan 2008

Study finds most psychiatric patients have more than one diagnosis

A new study by Rhode Island Hospital researchers reports that the majority of 2,300 psychiatry outpatients had more than one disorder when seeking treatment, and more than one-third had at least three disorders.

15 Jan 2008

Help with getting off the couch

It's only been a few weeks since you made that New Year's resolution to exercise more, but already you're finding reasons to skip days - maybe even weeks.

10 Jan 2008

AstraZeneca submits sNDAs for SEROQUEL XR for bipolar symptoms

AstraZeneca has announced that the company has submitted two separate supplemental New Drug Applications (sNDAs) to the U.S. Food and Drug Administration (FDA) for once-daily SEROQUEL XR (quetiapine fumarate) Extended-Release Tablets to seek approval for the treatment of manic episodes associated with bipolar disorder and the treatment of depressive episodes associated with bipolar disorder.

3 Jan 2008

Omega-3 fatty acids for depression - new trial

Researchers at Cedars-Sinai Medical Center's Department of Psychiatry and Behavioral Neurosciences are seeking participants for a clinical trial examining whether two polyunsaturated Omega-3 fatty acids are effective treatments for depression.

18 Dec 2007

Venlafaxine extended-release effective for patients with major depression

Major depressive disorder (MDD) is the most common major mental illness, afflicting almost one in five individuals.

13 Dec 2007

Relationship of female sex hormones to mood states and disorders merits better research

Countless movies and TV shows make light of women's so-called “moodiness”, often jokingly attributing it to their menstrual cycle or, conversely, to menopause.

13 Dec 2007

New studies on brain and behavior from the world's leading scientists

The 2007 American College of Neuropsychopharmacology Annual Meeting will feature hundreds of new studies on brain and behavior from the world's leading scientists.

10 Dec 2007

Stable sleep patterns and regular routines may improve outcomes in bipolar disorder

Bipolar disorder, commonly known as manic-depressive disorder, is highly influenced by the circadian system - the body's internal clock - and a specific kind of psychotherapy may help decrease irregularities in the circadian system that can trigger key symptoms of bipolar disorder, according to a study presented at the American College of Neuropsychopharmacology (ACNP) annual meeting.

10 Dec 2007

New psychiatric medication treatment guidelines for preschoolers

The number of preschool-age children being treated with stimulants, antidepressants and other psychiatric drugs is on the rise, despite limited research and a lack of clinical practice guidelines.

4 Dec 2007

FDA approves Cymbalta for maintenance treatment of major depressive disorder

Eli Lilly and Company has announced that the U.S. Food and Drug Administration (FDA) has approved Cymbalta (duloxetine HCl) for the maintenance treatment of major depressive disorder (MDD) in adults.

2 Dec 2007

FDA accepts Schering-Plough's new drug application for Asenapine

Schering-Plough Corporation has announced that the U.S. Food and Drug Administration (FDA) recently accepted the filing for review of the New Drug Application (NDA) for asenapine, a fast-dissolving, sublingual tablet.

26 Nov 2007

Trial of the antidepressant fluoxetine for teens with depression and substance use disorders

The antidepressant fluoxetine combined with cognitive behavioral therapy appears as effective for treating depression among teens who also have substance use disorders as among those without substance abuse problems, according to a report in the November issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.

6 Nov 2007

Fabre Kramer Pharmaceuticals receives FDA decision on Gepirone ER for major depressive disorder

Fabre-Kramer Pharmaceuticals Inc. (FKP) and GlaxoSmithKline announced today that the U.S. Food and Drug Administration (FDA) has issued a not approvable letter for the new drug application for gepirone extended- release (ER) tablets, submitted for the treatment of adults with major depressive disorder.

5 Nov 2007

Depressed adolescents respond best to psychotherapy and antidepressant medication

A combination of psychotherapy and antidepressant medication appears to be the most effective treatment for adolescents with major depressive disorder - more than medication alone or psychotherapy alone, according to results from a major clinical trial funded by the National Institutes of Health's National Institute of Mental Health (NIMH).

2 Oct 2007